<DOC>
	<DOCNO>NCT00107458</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , valproic acid , work different way stop growth tumor cell , either kill cell stop dividing . Valproic acid may also stop growth solid tumor CNS tumor block blood flow tumor . PURPOSE : This phase I trial study side effect best dose valproic acid treat patient recurrent refractory solid tumor CNS tumor .</brief_summary>
	<brief_title>Valproic Acid Treating Young Patients With Recurrent Refractory Solid Tumors CNS Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxic effect valproic acid ( VPA ) administer dos require maintain serum trough VPA concentration 100-150 mcg/mL 150-200 mcg/mL young patient recurrent refractory solid tumor CNS tumor . Secondary - Determine steady-state serum trough concentration free total VPA target total trough VPA concentration patient . - Determine steady state histone acetylation status peripheral blood monocyte target trough VPA concentration patient . - Determine pharmacokinetic profile drug patient . - Correlate histone acetylation free total trough VPA concentration patient . - Determine , preliminarily , antitumor activity drug patient . OUTLINE : This dose-escalation , multicenter study . For course 1 , patient receive escalate dos oral valproic acid ( VPA ) twice daily target serum trough VPA concentration range maintain 28 day . Patients achieve target serum trough VPA concentration range receive subsequent course oral VPA twice daily ( dose find maintain target serum trough VPA concentration range ) day 1-28 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . The first cohort 6 patient receive VPA achieve initial target trough serum VPA concentration . If few 2 6 patient first cohort experience dose-limiting toxicity ( DLT ) , second cohort 6 patient receive VPA achieve next high target trough serum VPA concentration . If few 2 patient second cohort experience DTL , 6 additional patient enrol cohort well define pharmacokinetics DLT VPA concentration range . After completion study treatment , patient follow annually . PROJECTED ACCRUAL : A total 12-18 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* malignant solid tumor , include CNS tumor , original diagnosis relapse Recurrent refractory disease NOTE : *Histologic confirmation require intrinsic brain stem optic pathway tumor Measurable evaluable disease , define 1 follow criterion : Any unidimensionally measurable lesion ≥ 10 mm standard MRI CT scan either solid CNS tumor At least 1 nonmeasurable lesion evaluable nuclear medicine , immunocytochemistry , tumor marker , cerebrospinal fluid cytology , reliable measure No know curative therapy exist No documented tumor involvement bone marrow PATIENT CHARACTERISTICS : Age 2 21 Performance status* Lansky 50100 % ( patient ≤ 10 year age ) Karnofsky 50100 % ( patient &gt; 10 year age ) Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion independent ) Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 110 ( ULN study 45 U/L ) Albumin ≥ 2 g/dL Renal Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR Creatinine base age follow : No great 0.8 mg/dL ( patient ≤ 5 year age ) No great 1.0 mg/dL ( patient 6 10 year age ) No great 1.2 mg/dL ( patient 11 15 year age ) No great 1.5 mg/dL ( patient 15 year age ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Neurologic deficits patient CNS tumor must stable ≥ 1 week study entry No uncontrolled infection No known urea cycle disorder metabolic disorder No condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Recovered prior immunotherapy At least 7 day since prior hematopoietic growth factor support platelet WBC number function At least 7 day since prior antineoplastic biologic agent At least 3 month since prior stem cell transplantation rescue without total body irradiation No evidence active graft v host disease No concurrent anticancer biologic therapy immunotherapy Chemotherapy More 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) recover No concurrent anticancer chemotherapy Endocrine therapy Patients CNS tumor must stable decrease dose dexamethasone past 7 day Radiotherapy See Biologic therapy Recovered prior radiotherapy At least 6 month since prior total body irradiation , craniospinal radiotherapy , radiotherapy ≥ 50 % pelvis At least 6 week since prior substantial bone marrow radiotherapy At least 2 week since prior local palliative small port radiotherapy No concurrent anticancer radiotherapy Surgery Not specify Other No concurrent investigational agent No concurrent anticancer agents No concurrent anticonvulsant Patients receive valproic acid ( VPA ) study entry must total trough VPA concentration &lt; 100 mcg/mL within past 7 day</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood spinal cord neoplasm</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
</DOC>